A pilot single-center study reported that adding contrast-enhanced ultrasound features improved discrimination among benign, borderline, and malignant ovarian adnexal masses when standard IOTA simple rules left cases indeterminate. The work suggests that vascular and contrast-associated imaging patterns can refine risk assessment without immediate reliance on biopsy. While the sample size remains limited to 90 patients and requires broader validation, the direction is clinically relevant: better pre-surgical categorization can influence triage to surgery, referral, and follow-up planning. For imaging-focused biotech and diagnostics teams, the signal is a renewed push for multimodal imaging markers that can be implemented in routine workflows if reproducibility holds.